Form 8-K
8-K — Viridian Therapeutics, Inc.\DE
Accession: 0001193125-26-336691
Filed: 2026-08-06
Period: 2026-08-06
CIK: 0001590750
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — d174744d8k.htm (Primary)
EX-99.1 (d174744dex991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d174744d8k.htm · Sequence: 1
8-K
Viridian Therapeutics, Inc.\DE false 0001590750 0001590750 2026-08-06 2026-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
VIRIDIAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36483
47-1187261
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
221 Crescent Street, Suite 103A
Waltham, MA
02453
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (617) 272-4600
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.01 par value
VRDN
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition
On August 6, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended June 30, 2026.
The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this Current Report on Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release, dated August 6, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Viridian Therapeutics, Inc.
Date: August 6, 2026
By:
/s/ Stephen Mahoney
Stephen Mahoney
President and Chief Executive Officer
EX-99.1
EX-99.1
Filename: d174744dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Viridian Therapeutics Highlights Recent Business Progress and Reports Second
Quarter 2026 Financial Results
- Lumvoa™ (veligrotug-vvze) approved by
the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of
target PDUFA date and immediately launched in the U.S. -
- Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA
submission Q1 2027 -
-
Pipeline progress continues, with FcRn and TSHR program development milestones on track in 2026 -
- Completed convertible debt and
equity financing in May 2026 with gross proceeds of $394 million; cash,
cash equivalents, and marketable securities of
$982 million as of June 30, 2026 -
WALTHAM, Mass. – August 6, 2026 – Viridian Therapeutics, Inc. (Nasdaq: VRDN), a
biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent
business highlights and financial results for the second quarter ended June 30, 2026.
“We are very encouraged by the early indications from
our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “Our team’s focus on execution continues in the
commercial setting and we are happy with the early launch feedback from physicians and patients, positive payer engagement, and our progress in building enthusiasm for Lumvoa as a new treatment option. In parallel, we continue to advance our R&D
pipeline toward a planned BLA submission for elegrobart in the first quarter of 2027, and are on track to deliver on clinical development milestones for our FcRn and TSHR programs in the second half of this year. With a strong balance sheet, we are
well positioned to continue executing across our commercial and development priorities.”
Recent Business Highlights
TED PORTFOLIO
•
Lumvoa: commercial launch in the U.S. with strong early momentum
•
The U.S. Food and Drug Administration (FDA) approved Lumvoa for the treatment of TED on June 26, 2026.
•
In the early stages of launch, the Viridian commercial team is focused on physician engagement, advancement of
payer policy adoption, and generation of market demand. As of July 31, 2026:
•
The field sales team achieved engagement with 95% of the 2,000 core prescribing physicians with strong and
positive early feedback.
•
Market access efforts to gain payer coverage are on track.
•
The first doses of Lumvoa were administered in July, and patient enrollment forms
to-date indicate broad and strong physician demand.
•
ViridianCares™, Viridian’s comprehensive patient
support program, was activated at the time of approval to help patients, physician offices, and infusion centers navigate insurance coverage and provide personalized assistance along the Lumvoa treatment journey.
•
Elegrobart (VRDN-003): BLA submission on track for Q1 2027
•
Viridian is on track to submit a Biologics License Application (BLA) to the FDA for elegrobart in Q1 2027.
•
Reported positive topline results from REVEAL-1 and REVEAL-2, two pivotal phase 3 clinical trials of subcutaneous elegrobart in active and chronic TED, respectively. At week 24 in both REVEAL-1 and REVEAL-2, Q4W and Q8W elegrobart demonstrated rapid and robust reductions in proptosis, and Q4W elegrobart additionally showed meaningful benefits for patients with diplopia. Elegrobart was generally well tolerated
with a safety profile consistent with the anti-IGF-1R class.
•
Elegrobart has the potential to be the first low-volume, subcutaneous
autoinjector for the treatment of TED that patients can self-administer at home, if approved.
•
Viridian anticipates that its current commercial and medical affairs infrastructure will support and accelerate a
potential elegrobart launch with limited incremental investment.
•
TSHR program: IND submission anticipated in Q4 2026
•
Viridian is developing a potential
best-in-class, half-life extended, monoclonal anti-thyroid-stimulating hormone receptor (TSHR) antibody, designed for subcutaneous delivery in an autoinjector with the
potential to support extended dosing intervals for patient convenience.
•
Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026 and expects to develop this
program in TED and Graves’ disease.
FCRN PORTFOLIO
•
VRDN-008: phase 1 healthy volunteer data expected in 2H 2026
•
VRDN-008 phase 1 clinical trial in healthy volunteers is ongoing. Data
remains on track for 2H 2026.
•
VRDN-008 is a bi-specific,
half-life extended FcRn inhibitor. As previously disclosed, after a single, high-dose head-to-head study in non-human primates, VRDN-008 showed a longer half-life and more sustained IgG reduction versus efgartigimod.
•
VRDN-006: development plan on track for disclosure in 2026
•
In a phase 1 healthy volunteer clinical trial, VRDN-006 showed IgG
reductions consistent with the FcRn inhibitor class, spared albumin and LDL, and was generally well-tolerated.
•
Viridian anticipates sharing development plans for VRDN-006 in 2026.
Financial Results
•
Cash Position: Cash, cash equivalents, and marketable securities were $981.5 million as of
June 30, 2026, compared with $762.2 million as of March 31, 2026. Existing cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to fund Viridian’s current business plans through
profitability.
•
R&D Expenses: Research and development expenses were $71.6 million for the three months ended
June 30, 2026, compared to $86.6 million for the three months ended June 30, 2025. The decrease in research and development expenses was driven by reduced expenses related to veligrotug and elegrobart studies, partially offset by
additional investment in advancing our TSHR program, as well as increased personnel-related costs as a result of headcount increases.
•
SG&A Expenses: Selling, general and administrative expenses for the three months ended June 30,
2026 were $55.0 million, compared with $20.2 million for the three months ended June 30, 2025. The increase in selling, general and administrative expenses was driven by increased personnel-related costs and build-out of commercial infrastructure for Lumvoa.
•
Net Loss: Net loss for the three months ended June 30, 2026, was $127.1 million, compared
with $100.7 million for the three months ended June 30, 2025.
•
Shares Outstanding: As of June 30, 2026, Viridian had 125,349,092 shares of common stock outstanding
on an as-converted basis, which included 113,238,218 shares of common stock and an aggregate 12,110,874 shares of common stock issuable upon the conversion of 181,654 total shares of preferred stock.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our
expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.
With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the
U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a
pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Viridian is headquartered in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian
on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to,
“anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,”
“on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that
concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements
include, without limitation, statements regarding: the commercialization of Lumvoa, including early indications of launch; that the company’s current commercial and medical affairs infrastructure will support and accelerate an elegrobart
launch; preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates, elegrobart, VRDN-006, and VRDN-008,
including the company’s intention to communicate development plans for VRDN-006 in 2026; anticipated data results and timing of their disclosure, including
VRDN-008 phase 1 healthy volunteer data expected in the second half of 2026; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a
BLA submission for elegrobart in the first quarter of 2027 and an IND submission for the company’s TSHR program in the fourth quarter of 2026; elegrobart’s potential to be the first subcutaneous therapy for the treatment of TED with a
planned low-volume autoinjector that patients can self-administer at home; Viridian’s product candidates potentially being
best-in-class; Viridian’s expectations regarding the potential commercialization, market size, and market opportunities of veligrotug and elegrobart, if approved;
and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties
(expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically
incurred losses and may not be able to secure additional capital when needed; that prior to marketing approval of veligrotug, the company had not generated revenue from product sales; that the company may be unable to maintain commercial
manufacturing, sales and marketing capabilities or enter into agreements with third parties to commercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits,
clinical response, and convenience of veligrotug and Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary
data may not be representative of final data; the timing,
progress and plans for our ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes
regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory
delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market
opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our financial position; our future operating results and financial performance; Viridian’s
intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the
“Risk Factors” section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made.
Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by
law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.
Viridian Therapeutics, Inc.
Condensed Consolidated Statements Of Operations
(In thousands, except share and per share data)
(Unaudited)
Three Months Ended
June 30,
2026
2025
Revenues:
License revenue
$
233
$
—
Collaboration revenue - related parties
51
75
Total revenues
284
75
Operating expenses:
Research and development
71,577
86,626
Selling, general and administrative
54,975
20,216
Total operating expenses
126,552
106,842
Loss from operations
(126,268
)
(106,767
)
Total other income (expense), net
(851
)
6,032
Net loss
$
(127,119
)
$
(100,735
)
Net loss allocated to common stock
$
(112,824
)
$
(81,978
)
Net loss per share, basic and diluted, common stock
$
(1.05
)
$
(1.00
)
Weighted-average common shares outstanding, basic and diluted
107,884,104
81,593,463
Net loss allocated to Series A convertible preferred stock
$
(9,395
)
$
(9,034
)
Net loss per share, basic and diluted, Series A convertible preferred stock
$
(69.72
)
$
(66.99
)
Weighted-average Series A convertible preferred stock outstanding, basic and diluted
134,754
134,864
Net loss allocated to Series B convertible preferred stock
$
(4,899
)
$
(9,723
)
Net loss per share, basic and diluted, Series B convertible preferred stock
$
(69.72
)
$
(66.98
)
Weighted-average Series B convertible preferred stock outstanding, basic and diluted
70,270
145,160
Viridian Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
June 30,
2026
December 31,
2025
Cash, cash equivalents and marketable securities
$
981,530
$
874,652
Other receivable
75,000
—
Other assets
40,703
24,766
Total assets
$
1,097,233
$
899,418
Total liabilities
435,136
177,251
Total stockholders’ equity
662,097
722,167
Total liabilities and stockholders’ equity
$
1,097,233
$
899,418
Contacts
Investors
Greg Rossino
grossino@viridiantherapeutics.com
Media
Lisa Lopez
llopez@viridiantherapeutics.com
Source: Viridian Therapeutics,
Inc.
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Document and Entity Information
Aug. 06, 2026
Cover [Abstract]
Entity Registrant Name
Viridian Therapeutics, Inc.\DE
Amendment Flag
false
Entity Central Index Key
0001590750
Document Type
8-K
Document Period End Date
Aug. 06, 2026
Entity Incorporation State Country Code
DE
Entity File Number
001-36483
Entity Tax Identification Number
47-1187261
Entity Address, Address Line One
221 Crescent Street
Entity Address, Address Line Two
Suite 103A
Entity Address, City or Town
Waltham
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02453
City Area Code
(617)
Local Phone Number
272-4600
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common Stock, $0.01 par value
Trading Symbol
VRDN
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration